Theranostic Outcomes in Clinical Practice of Oncology: What, So What, Now What? What's More

被引：6

作者：

Turner, J. Harvey ^{[1
]}

机构：

[1] Univ Western Australia, Nedlands, WA, Australia

来源：

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS | 2019年 / 34卷 / 03期

关键词：

NON-HODGKIN-LYMPHOMA; PHASE-II; THERAPY; RADIOIMMUNOTHERAPY; I-131-RITUXIMAB; LU-177-DOTATATE; CAPECITABINE; SURVIVAL;

D O I：

10.1089/cbr.2019.29006.jht

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：135 / 140

页数：6

共 42 条

[1] To all involved - we have a problem [J].

不详 .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (07) :397-397

[2]

[Anonymous], 2017, BLOOD S1

[3]

[Anonymous], 2018, J CLIN ONCOL S

[4]

Basch E, 2018, LANCET ONCOL, V19, P595, DOI 10.1016/S1470-2045(18)30141-4

[5] Optimal time-point for 68Ga-PSMA-11 PET/CT imaging in assessment of prostate cancer: feasibility of sterile cold-kit tracer preparation? [J].

Beheshti, Mohsen ;

Paymani, Zeinab ;

Brilhante, Joana ;

Geinitz, Hans ;

Gehring, Daniela ;

Leopoldseder, Thomas ;

Wouters, Ludovic ;

Pirich, Christian ;

Loidl, Wolfgang ;

Langsteger, Werner .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (07) :1188-1196

[6] Real-world data: towards achieving the achievable in cancer care [J].

Booth, Christopher M. ;

Karim, Safiya ;

Mackillop, William J. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (05) :312-325

[7] Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0, Tyr3] octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors [J].

Brabander, Tessa ;

van der Zwan, Wouter A. ;

Teunissen, Jaap J. M. ;

Kam, Boen L. R. ;

Feelders, Richard A. ;

de Herder, Wouter W. ;

van Eijck, Casper H. J. ;

Franssen, Gaston J. H. ;

Krenning, Eric P. ;

Kwekkeboom, Dik J. .

CLINICAL CANCER RESEARCH, 2017, 23 (16) :4617-4624

[8] Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score [J].

Cherny, Nathan I. ;

de Vries, Elisabeth G. E. ;

Dafni, Urania ;

Garrett-Mayer, Elizabeth ;

McKernin, Shannon E. ;

Piccart, Martine ;

Latino, Nicola J. ;

Douillard, Jean-Yves ;

Schnipper, Lowell E. ;

Somerfield, Mark R. ;

Bogaerts, Jan ;

Karlis, Dimitris ;

Zygoura, Panagiota ;

Vervita, Katerina ;

Pentheroudakis, George ;

Tabernero, Josep ;

Zielinski, Christoph ;

Wollins, Dana S. ;

Schilsky, Richard L. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04) :336-+

[9] Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy [J].

Claringbold, Phillip G. ;

Turner, J. Harvey .

NEUROENDOCRINOLOGY, 2016, 103 (05) :432-439

[10] Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours [J].

Claringbold, Phillip G. ;

Brayshaw, Paul A. ;

Price, Richard A. ;

Turner, J. Harvey .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (02) :302-311

← 1 2 3 4 5 →